Clinical Trial

A Study of GV20-0251 in Advanced or Refractory Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a single-arm, single-center study for multiple tumor indications to evaluate the safety of GV20-0251. The trial uses a 3 + 3 design and enrolls 3-6 patients in the 10 mg/kg and 20 mg/kg dose groups, respectively. The cancer types include solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-29.
Status change: Not Yet Recruiting → Recruiting 2025-11-18
Trial Details
NCT Number NCT07106827
Lead Sponsor West China Hospital
Collaborators: GV20 Therapeutics
Conditions HCC - Hepatocellular Carcinoma, Cholangiocarcinoma, Melanoma, NSCLC (Non-small Cell Lung Cancer), Pancreatic Ductal Adenocarcinoma, HNSCC, Endometrial Cancer, Testicular Cancer
Enrollment 10 participants
Start Date 2025-09-04
Primary Completion 2027-06-11 (estimated)
Study Completion 2028-06-11 (estimated)
Updated on ClinicalTrials.gov 2025-11-24